NHC director receives 7,500 stock options grant
NATIONAL HEALTHCARE CORP director Sandra Y. Trail reported a compensation-related award of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
NATIONAL HEALTHCARE CORP director Sandra Y. Trail reported a compensation-related award of stock options. She received an option to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, granted under the 2020 Omnibus Equity Incentive Plan on May 7, 2026.
The option becomes exercisable on May 7, 2027 and expires on May 6, 2031. Following this filing, Trail holds 7,500 shares of common stock directly and has several prior option grants outstanding with exercise prices of $94.66, $96.03, and $55.75 per share, each covering 7,500 underlying shares. The company notes the grant and its potential exercise are exempt from Section 16(b) under Rule 16b-3(d).
Insider Trade Summary
Grant/Award: 7,500 shares
Grant/Award
5 txns
Insider
Trail Sandra Y.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock [2026 Grant] | 7,500 | $0.00 | $0.00 |
| holding | Option to Purchase Common Stock [2023 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2024 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2025 Grant] | -- | -- | -- |
| holding | Shares of Common Stock | -- | -- | -- |
Holdings After Transaction:
Option to Purchase Common Stock [2026 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2023 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2024 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2025 Grant] — 7,500 contracts (Direct);
Shares of Common Stock — 7,500 shares (Direct)
Footnotes (1)
- F1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).
Key Figures
New option grant size: 7,500 options
New option exercise price: $171.42 per share
New option term: May 7, 2027–May 6, 2031
+4 more
7 metrics
New option grant size
7,500 options
2026 grant to director Sandra Y. Trail
New option exercise price
$171.42 per share
2026 grant exercise price
New option term
May 7, 2027–May 6, 2031
Exercisable period for 2026 grant
Common shares held
7,500 shares
Total shares following transaction
2025 grant exercise price
$94.66 per share
Option to purchase 7,500 shares, expires 2030-05-07
2024 grant exercise price
$96.03 per share
Option to purchase 7,500 shares, expires 2029-05-08
2023 grant exercise price
$55.75 per share
Option to purchase 7,500 shares, expires 2028-05-03
Key Terms
2020 Omnibus Equity Incentive Plan, Section 16(b), Rule 16b-3(d), stock options
4 terms
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026."
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d)."
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d)."
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
stock options financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NATIONAL HEALTHCARE CORP (NHC) director Sandra Y. Trail report on this Form 4?
Sandra Y. Trail reported receiving a stock option grant for 7,500 shares of NATIONAL HEALTHCARE CORP common stock. The award is a compensation-related option, not an open-market stock purchase or sale, and was granted under the 2020 Omnibus Equity Incentive Plan.
What are the key terms of Sandra Y. Trail’s new NHC stock option grant?
The new option covers 7,500 underlying shares at an exercise price of $171.42 per share. It becomes exercisable on May 7, 2027 and will expire on May 6, 2031, giving Trail several years to decide whether to exercise.
What other stock option grants does Sandra Y. Trail have at NHC?
Alongside the 2026 grant, Trail has prior options labeled 2023, 2024, and 2025 grants. Each relates to 7,500 underlying shares, with exercise prices of $55.75, $96.03, and $94.66 per share and expirations in 2028, 2029, and 2030.
Is Sandra Y. Trail’s new NHC stock option grant exempt from Section 16(b)?
Yes. The footnote states these stock options were granted under the 2020 Omnibus Equity Incentive Plan and that the grant and exercise are exempt from Section 16(b) short-swing profit rules pursuant to Rule 16b-3(d).
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates